Upstate Active Clinical Trials

Study Title:

Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

What is the purpose of the study?

Randomized treatment study to compare the effectiveness of chemotherapy with or without monoclonal antibody, interleukin-2, and sargramostim following stem cell transplantation in treating patients who have neuroblastoma.

Upstate Institutional Review Board (IRB) Number:

229602

Study/Protocol ID:

ANBL0032

Study Phase:

III

Patient Age Group:

Children

Principal Investigator:

Karol H Kerr, MD

ClinicalTrials.Gov ID:

NCT00026312

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Beatriz Kovar
Phone: 315-464-7232
Email: kovarb@upstate.edu

Return to Previous Page || Search Again